*ST长药:子公司羿珩科技近日决定实行停产

Core Viewpoint - *ST Changyao's subsidiary, Yiheng Technology, has decided to suspend production due to the competitive environment in the photovoltaic industry and its own financial difficulties, aiming to reduce operational costs and protect shareholder interests [1][2]. Group 1: Company Operations - Yiheng Technology primarily operates in the photovoltaic product sector, and its suspension of production will not adversely affect the company's pharmaceutical operations [2]. - The decision to suspend production is a strategic move to minimize ongoing losses and reduce the negative impact on the company's overall performance [2]. - The company has arranged for Yiheng Technology's management team to remain in place during the suspension to ensure stability and protect existing assets and employee rights [2]. Group 2: Financial Implications - Yiheng Technology is currently in a state of loss and facing tight operational funding, making it difficult to return to profitability in the short term [2]. - The suspension of production is expected to decrease the company's operational losses and avoid further financial strain from continued production [2]. - The company plans to assess market conditions to determine whether to resume production and is actively seeking external cooperation opportunities to maximize the remaining asset value [2].